Delayed IGF-1 treatment reduced long-term hypoxia-ischemia-induced brain damage and improved behavior recovery of immature rats

Jin Zhong, Limin Zhao, Yansheng Du, Gang Wei, Wei Guo Yao, Wei Hua Lee

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Cerebral hypoxia-ischemia during the perinatal period is the single most important cause of acute newborn mortality and chronic disability. Despite our increasing understanding of the mechanisms of neuronal injury, an effective clinical therapy has yet to be established to mitigate brain damage and improve the prognosis and well-being of these newborn patients. Insulin-like growth factor 1 (IGF-1) is a well-known neurotrophic factor, essential for the survival and functional maturation of immature neurons. This study demonstrated that subcutaneous administration of IGF-1 at 24 and 48 hours of recovery significantly reduced hypoxia-ischemia-induced injury to immature rat brains and improved long-term memory and cognitive behavior. IGF-1's therapeutic effects likely involve its ability to prevent delayed apoptosis, as we demonstrated in primary cortical neuronal cultures under oxygen and glucose deprivation. IGF-1's neuroprotective effects parallel the activities of phosphatidylinositol-3/Akt and its downstream signaling pathway, suggesting a potential mechanistic link. Overall, evidence from this investigation strongly supports IGF-1's potential therapeutic use in the treatment of hypoxic-ischemic encephalopathy in newborn patients.

Original languageEnglish
Pages (from-to)483-489
Number of pages7
JournalNeurological Research
Volume31
Issue number5
DOIs
StatePublished - Jun 2009

Fingerprint

Brain Hypoxia-Ischemia
Somatomedins
Newborn Infant
Therapeutic Uses
Therapeutics
Aptitude
Long-Term Memory
Nerve Growth Factors
Wounds and Injuries
Brain
Neuroprotective Agents
Phosphatidylinositols
Ischemia
Apoptosis
Oxygen
Neurons
Glucose
Survival
Mortality

Keywords

  • Apoptosis
  • Brain
  • Hypoxic-ischemic encephalopathy
  • Insulin like growth factor-1
  • Stroke

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Delayed IGF-1 treatment reduced long-term hypoxia-ischemia-induced brain damage and improved behavior recovery of immature rats. / Zhong, Jin; Zhao, Limin; Du, Yansheng; Wei, Gang; Yao, Wei Guo; Lee, Wei Hua.

In: Neurological Research, Vol. 31, No. 5, 06.2009, p. 483-489.

Research output: Contribution to journalArticle

Zhong, Jin ; Zhao, Limin ; Du, Yansheng ; Wei, Gang ; Yao, Wei Guo ; Lee, Wei Hua. / Delayed IGF-1 treatment reduced long-term hypoxia-ischemia-induced brain damage and improved behavior recovery of immature rats. In: Neurological Research. 2009 ; Vol. 31, No. 5. pp. 483-489.
@article{35fbb314be6741d6a946dbe991868e50,
title = "Delayed IGF-1 treatment reduced long-term hypoxia-ischemia-induced brain damage and improved behavior recovery of immature rats",
abstract = "Cerebral hypoxia-ischemia during the perinatal period is the single most important cause of acute newborn mortality and chronic disability. Despite our increasing understanding of the mechanisms of neuronal injury, an effective clinical therapy has yet to be established to mitigate brain damage and improve the prognosis and well-being of these newborn patients. Insulin-like growth factor 1 (IGF-1) is a well-known neurotrophic factor, essential for the survival and functional maturation of immature neurons. This study demonstrated that subcutaneous administration of IGF-1 at 24 and 48 hours of recovery significantly reduced hypoxia-ischemia-induced injury to immature rat brains and improved long-term memory and cognitive behavior. IGF-1's therapeutic effects likely involve its ability to prevent delayed apoptosis, as we demonstrated in primary cortical neuronal cultures under oxygen and glucose deprivation. IGF-1's neuroprotective effects parallel the activities of phosphatidylinositol-3/Akt and its downstream signaling pathway, suggesting a potential mechanistic link. Overall, evidence from this investigation strongly supports IGF-1's potential therapeutic use in the treatment of hypoxic-ischemic encephalopathy in newborn patients.",
keywords = "Apoptosis, Brain, Hypoxic-ischemic encephalopathy, Insulin like growth factor-1, Stroke",
author = "Jin Zhong and Limin Zhao and Yansheng Du and Gang Wei and Yao, {Wei Guo} and Lee, {Wei Hua}",
year = "2009",
month = "6",
doi = "10.1179/174313208X338133",
language = "English",
volume = "31",
pages = "483--489",
journal = "Neurological Research",
issn = "0161-6412",
publisher = "Maney Publishing",
number = "5",

}

TY - JOUR

T1 - Delayed IGF-1 treatment reduced long-term hypoxia-ischemia-induced brain damage and improved behavior recovery of immature rats

AU - Zhong, Jin

AU - Zhao, Limin

AU - Du, Yansheng

AU - Wei, Gang

AU - Yao, Wei Guo

AU - Lee, Wei Hua

PY - 2009/6

Y1 - 2009/6

N2 - Cerebral hypoxia-ischemia during the perinatal period is the single most important cause of acute newborn mortality and chronic disability. Despite our increasing understanding of the mechanisms of neuronal injury, an effective clinical therapy has yet to be established to mitigate brain damage and improve the prognosis and well-being of these newborn patients. Insulin-like growth factor 1 (IGF-1) is a well-known neurotrophic factor, essential for the survival and functional maturation of immature neurons. This study demonstrated that subcutaneous administration of IGF-1 at 24 and 48 hours of recovery significantly reduced hypoxia-ischemia-induced injury to immature rat brains and improved long-term memory and cognitive behavior. IGF-1's therapeutic effects likely involve its ability to prevent delayed apoptosis, as we demonstrated in primary cortical neuronal cultures under oxygen and glucose deprivation. IGF-1's neuroprotective effects parallel the activities of phosphatidylinositol-3/Akt and its downstream signaling pathway, suggesting a potential mechanistic link. Overall, evidence from this investigation strongly supports IGF-1's potential therapeutic use in the treatment of hypoxic-ischemic encephalopathy in newborn patients.

AB - Cerebral hypoxia-ischemia during the perinatal period is the single most important cause of acute newborn mortality and chronic disability. Despite our increasing understanding of the mechanisms of neuronal injury, an effective clinical therapy has yet to be established to mitigate brain damage and improve the prognosis and well-being of these newborn patients. Insulin-like growth factor 1 (IGF-1) is a well-known neurotrophic factor, essential for the survival and functional maturation of immature neurons. This study demonstrated that subcutaneous administration of IGF-1 at 24 and 48 hours of recovery significantly reduced hypoxia-ischemia-induced injury to immature rat brains and improved long-term memory and cognitive behavior. IGF-1's therapeutic effects likely involve its ability to prevent delayed apoptosis, as we demonstrated in primary cortical neuronal cultures under oxygen and glucose deprivation. IGF-1's neuroprotective effects parallel the activities of phosphatidylinositol-3/Akt and its downstream signaling pathway, suggesting a potential mechanistic link. Overall, evidence from this investigation strongly supports IGF-1's potential therapeutic use in the treatment of hypoxic-ischemic encephalopathy in newborn patients.

KW - Apoptosis

KW - Brain

KW - Hypoxic-ischemic encephalopathy

KW - Insulin like growth factor-1

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=67650165314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650165314&partnerID=8YFLogxK

U2 - 10.1179/174313208X338133

DO - 10.1179/174313208X338133

M3 - Article

C2 - 19500451

AN - SCOPUS:67650165314

VL - 31

SP - 483

EP - 489

JO - Neurological Research

JF - Neurological Research

SN - 0161-6412

IS - 5

ER -